|
---|
Category:Letter
MONTHYEARML24264A1712024-09-20020 September 2024 Framatome, Inc. - License Amendment Request for TRISO Fuel Production at the Framatome Fuel Fabrication Facility in Richland, Wa ML24211A0592024-07-29029 July 2024 Framatome Inc. – Physical Security Core Inspection Report 07001257-2024401 Public ML24190A0292024-07-19019 July 2024 Framatome - Richland - Core Inspection Report 07001257/2024002 ML24179A1172024-06-27027 June 2024 Framatome-Richland – Inspection Schedule for Calendar Year 2025 ML24116A2922024-04-29029 April 2024 Framatome-Richland - Core Inspection Report 07001257/2024001 ML24092A2752024-04-0303 April 2024 Acceptance for Review of Framatome, Incs Triennial Update to Decommissioning Funding Plan - Enterprise Project Identifier Number L-2024-DFA-0000 ML24065A4842024-03-0808 March 2024 Framatome Inc. - Licensee Performance Review - Nuclear Regulatory Commission Inspection Report 07001257/2024005 ML24026A2792024-01-31031 January 2024 Framatome - Richland – Integrated Inspection Report 07001257/2023004 ML24031A5432024-01-23023 January 2024 Triennial Update to Decommissioning Funding Plan (DFP) for the Framatome Inc., Richland Nuclear Fuel Fabrication Facility Cover Letter ML23352A3912023-12-20020 December 2023 Framatome Inc. - Richland Material Control and Accounting Program Inspection Report 07001257-2023401-Public Cover Letter ML23313A0772023-11-27027 November 2023 Framatome Inc. - Request to Amend License and Approve Criticality Safety Methods - License Amendment 19 (Enterprise Project Identification Number L-2023-LLA-0073) ML23296A0072023-10-25025 October 2023 Framatome-Richland - Core Inspection Report 07001257/2023003 ML23291A2042023-10-18018 October 2023 Framatome Inc., Richland Nuclear Fuel Fabrication Facilitys Request to Amend License No. SNM-1227 and Approval of Criticality Safety Methods ML23255A2892023-09-15015 September 2023 Framatome-Richland – Inspection Schedule for Calendar Year 2024 ML23254A2502023-09-13013 September 2023 Request of Additional Information Letter to Framatome ML23202A2022023-07-24024 July 2023 Framatome Richland Core Inspection Report 07001257/2023002 ML23198A3172023-07-17017 July 2023 Framatome Inc. Richland Nuclear Fuel Fabrication Facilitys Revised Chapter 1 of License No. SNM-1227 ML23144A3092023-06-21021 June 2023 Acceptance Letter for Request by Framatome for a License Amendment for an Approval of Criticality Safety Methods ML23144A3372023-06-12012 June 2023 Letter to Framatome Approval of Request to Withhold Proprietary Information ML23145A3082023-06-0202 June 2023 Framatome - Licensing Project Manager Change Letter ML23137A3962023-05-17017 May 2023 Framatome, Inc., Richland Nuclear Fuel Fabrication Facility’S Request to Amend License No. SNM-1227; and Approval of Criticality Safety Methods ML23137A4062023-05-17017 May 2023 Framatome, Inc., Submittal of NRC Form 327s Which Report the Results of Material Balance Accounting and Seid Calculations for the Period March 22, 2022 to March 20, 2023 ML23089A2592023-04-10010 April 2023 2023-001 Framatome-Richland - NRC Integrated Inspection Report 07001257/2023001 ML23089A2602023-03-30030 March 2023 Framatome, Inc. - 2023 Fee Increase for Fuel Cycle Licensees; License No. SNM-1227; Docket No. 70-1257 ML23054A2562023-02-23023 February 2023 60-Day Report to January 2, 2023, Incident Reported Under 10 CFR 70 Appendix a Concurrent Report (NRC Event No. 56292); Framatome Richland Facility; License No. SNWI-1227; Docket No. 70-1257 ML22336A0992023-02-0303 February 2023 Cover Letter - Framatome Proprietary Approval 3x Letter of Intent Submittals 11/21/2022 and 11/29/2022 ML23030B6172023-01-31031 January 2023 Framatome-Richland - Core Inspection Report 07001257/2022004 ML23025A3172023-01-25025 January 2023 Submittal of Integrated Safety Analysis (ISA) Summary Annual Update for Framatome Inc.S (Framatomes) Richland, Washington Fuel Fabrication Facility ML22341A1562022-12-0707 December 2022 60-day Follow Up Report for an Incident Reported Under 10 CFR 70 Appendix a (C) Concurrent Report (NRC Event No.56713); Framatome Richland Facility ML22272A0252022-10-0404 October 2022 Framatome-Richland -Integrated Inspection Report 07001257/2022003 ML22263A4652022-09-20020 September 2022 Framatome, Inc. Submittal of Revised Fundamental Nuclear Material Control Plan ML22255A0122022-08-31031 August 2022 Framatome Inc. - Required Reporting of Effluents Per 10 CFR 70.59 ML22238A1602022-08-24024 August 2022 Framatome Richland Facility Emergency Plan Version 16.0 ML22236A5872022-08-23023 August 2022 Framatome Inc., Richland Nuclear Fuel Fabrication Facilitys Intent to Amend License No. SNM-1227; ML22201A5352022-07-21021 July 2022 Framatome 2022-002 Integrated Quarterly Inspection Report ML22192A1272022-07-11011 July 2022 Framatome, Inc., 60-day Report for a May 12, 2022 Incident Reported Under 10 CFR 70 Appendix a 24-hour Report (NRC Event No. 55897) ML22154A4382022-07-11011 July 2022 Cover Letter - Framatome Inc. - Request to Amend License and Approve Criticality Safety Methods - License Amendment 18 (Enterprise Project Identification Number L-2021-LLA-0218) ML22187A1892022-06-29029 June 2022 Framatome-Richland - Inspection Schedule for Calendar Year 2023 ML22187A0392022-06-28028 June 2022 Framatome Documentation Request - 2022-003 PMT ML22137A1282022-06-23023 June 2022 Cover Letter - Framatome- DFP Info and Form 327 Proprietary Review ML22166A3432022-06-10010 June 2022 Framatome Lnc., Submittal of Quality Assurance Program, FS1-0011462, Revision 8.0, 10 CFR 71, Subpart H Quality Assurance Program Description for Packaging and Transportation of Radioactive Materials for Us Fuel ML22132A2292022-05-12012 May 2022 Framatome, Inc., Submittal of NRC Form 327 ML22132A2952022-05-12012 May 2022 Framatome, Inc., Submittal of Triennial Update to Decommissioning Funding Plan (DFP) for the Richland Nuclear Fuel Fabrication Facility ML22087A1212022-03-31031 March 2022 Cover Letter Framatome Inc., - Request for Additional Information Regarding License Amendment Request for Approval of Criticality Safety Methods (Enterprise Project Identification Number L-2021-LLA-0218) ML22059A7582022-03-0303 March 2022 Framatome, Inc., Licensee Performance Review (Nuclear Regulatory Commission Inspection Report 0701257/2022005) ML22060A1262022-03-0101 March 2022 60-day Report to January 4, 2022 Incident Reported Under 10 CFR 70 Appendix a Concurrent Report (NRC Event No. 55686); Framatome Richland Facility; License No. SNM-1227; Docket No. 70-1257 ML22066B2732022-02-28028 February 2022 Framatome, Inc. - Required Reporting of Effluents Per 10 CFR 70.59 for July-December 2021 ML22033A1722022-01-27027 January 2022 Framatome, Inc. Richland Washington Fuel Fabrication Facility Submittal of Update to Integrated Safety Analysis (ISA) ML22025A3902022-01-25025 January 2022 60-day Report to January 4, 2022 Incident Reported Under 10 CFR 70 Appendix a Concurrent Report (NRC Event No. 55686); Framatome Richland Facility ML22024A2152022-01-25025 January 2022 Framatome, Inc. - Richland, U.S. Nuclear Regulatory Commission Integrated Inspection Report 07001257/2021004 2024-09-20
[Table view] |
Text
September 15, 2014 Ms. Janet R. Schlueter, Director Fuel and Materials Safety Nuclear Generation Division Nuclear Energy Institute 1201 F Street, NW Suite 1100 Washington, DC 20004
SUBJECT:
RESPONSE TO MARCH 26, 2014, NUCLEAR ENERGY INSTITUTE LETTER ON DERMAL AND OCULAR QUANTITATIVE EXPOSURE STANDARD
Dear Ms. Schlueter:
The U.S. Nuclear Regulatory Commission (NRC) staff has reviewed your letter dated March 26, 2014, and its enclosure, arguing that the Integrated Safety Analysis (ISA) need only consider inhalation pathways when analyzing for acute chemical exposures to NRC-licensed material, or chemicals produced from such material. You state that developing dermal and ocular exposure standards for use in demonstrating compliance with the performance requirements of Title 10 of the Code of Federal Regulations (10 CFR) Part 70, Subpart H, is impractical, unnecessary and constitutes an unanalyzed backfit. The staff has reviewed the NRC documentation supporting the development of the Subpart H rule, and finds that the rules requirements for analyzing chemical hazards (specifically, hazards arising from acute chemical exposures) are not limited to consideration of the inhalation pathway. The staff concludes that failure to consider all reasonable worker exposure pathways would create a regulatory gap in the oversight of chemical hazards that are under NRCs jurisdiction.
Neither the relevant Subpart H requirements, nor the NRCs interpretation of these requirements, have changed. However, even if the staffs position on dermal and ocular exposure pathways is deemed to be the imposition of a new regulatory position that falls within the definition of backfitting, the compliance exception stated in 10 CFR 70.76(a)(4)(i) would be applicable. The enclosure to this letter provides a detailed evaluation of the compliance backfit exception.
Accordingly, the staff will evaluate ISA summaries to ensure that the licensee has considered all reasonable exposure pathways in the ISA chemical hazard analysis. For all credible event consequences as defined in 10 CFR 70.61(b)(4) and (c)(4), the staff will review the ISA summary description of the proposed quantitative standards used to assess the consequences to an individual from acute chemical exposure to licensed material or chemicals produced from licensed materials, as stated in 10 CFR 70.65(b)(7). For license amendments, renewals or new applications such staff evaluations do not constitute backfitting.
The NRC is developing an Interim Staff Guidance (ISG) that addresses chemical exposures at fuel cycle facilities subject to Subpart H. The ISG will discuss the criteria staff will apply when reviewing event consequences and proposed quantitative standards used to assess the consequences to an individual from acute chemical exposure in the ISA. The ISG will provide
J. Schlueter guidance on the staff review of all credible exposure pathways to demonstrate compliance with 10 CFR 70.61. Development of this ISG should help promote a common understanding of proposed quantitative standards for non-inhalation pathways supporting chemical safety analyses in the ISA. The NRC will engage stakeholders, as appropriate, to discuss an implementation plan.
In accordance with 10 CFR 2.390 of the NRCs Agency Rules of Practice and Procedure, a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the Publicly Available Records component of NRCs Agencywide Documents Access and Management System (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.
Sincerely,
/RA/
Marissa G. Bailey, Director A.Blamey-for Division of Fuel Cycle Safety and Safeguards Office of Nuclear Material Safety and Safeguards Docket: 70-1257 License: SNM-1227
Enclosure:
Documented Evaluation for Compliance Backfit Exception
ML14251A145 Pkg.: ML14251A150 OFFICE FCSS/FMB FCSS/FMB/LA FCSS/FMB/BC OGC FCSS/DD NAME MDiaz TBrockington RJohnson JHull MBailey DATE 09/08/14 09/12/14 09/08/14 09/15/14 09/15 /14